The CD70/CD27 Pathway is Critical for Stimulation of an Effective Cytotoxic T Cell Response Against B Cell Precursor Acute Lymphoblastic Leukemia
Overview
Authors
Affiliations
For effective immunotherapy, maintaining the frequency and cytotoxic potential of effector cells is critical. In this context costimulation via the CD70/CD27 pathway has been proven essential. CD70 has been reported to be expressed to varying degrees on malignant B cells. However, in B cell precursor acute lymphoblastic leukemia, the most common childhood malignancy, the role of CD70 in stimulation of antileukemic T cell responses has so far not been delineated. Herein we demonstrate that in B cell precursor acute lymphoblastic leukemia expression of CD70 is low but can be induced upon blast activation via CD40. Both CD70 and CD80/CD86 up-regulated on CD40-stimulated blasts contribute to primary stimulation of T cell proliferation and cytokine production in an additive manner. These two signals also cooperate in the prevention of T cell anergy. In contrast to blockade of CD70 during the effector phase, inhibition of CD70-mediated costimulation during generation of antileukemic T cells prevents effector cell proliferation and reduces their cytotoxic capacity. Modulation of the CD70/CD27 pathway may thus represent a novel therapeutic approach for augmenting magnitude and quality of the antileukemic response in B cell precursor acute lymphoblastic leukemia.
Revolutionizing acute myeloid leukemia treatment: a systematic review of immune-based therapies.
Ebinama U, George B Discov Oncol. 2025; 16(1):89.
PMID: 39864030 PMC: 11769894. DOI: 10.1007/s12672-025-01797-9.
Soluble CD27 is an intrathecal biomarker of T-cell-mediated lesion activity in multiple sclerosis.
Cencioni M, Magliozzi R, Palmisano I, Suwan K, Mensi A, Fuentes-Font L J Neuroinflammation. 2024; 21(1):91.
PMID: 38609999 PMC: 11015621. DOI: 10.1186/s12974-024-03077-9.
Abobakr A, Osman R, Kamal M, Abdelhameed S, Ismail H, Kamel M Hematol Transfus Cell Ther. 2023; 46 Suppl 6:S27-S35.
PMID: 38065726 PMC: 11726023. DOI: 10.1016/j.htct.2023.10.003.
Cheng J, Ge T, Zhu X, Wang J, Zeng Y, Mu W Cancer Immunol Immunother. 2023; 72(7):2331-2346.
PMID: 36932256 PMC: 10264288. DOI: 10.1007/s00262-023-03422-6.
Stephan A, Kosinska A, Muck-Hausl M, Muschaweckh A, Jager C, Roder N Vaccines (Basel). 2023; 11(2).
PMID: 36851121 PMC: 9966001. DOI: 10.3390/vaccines11020245.